PE20030273A1 - Derivados de tetrahidroquinolina como moduladores de la hormona foliculo estimulante - Google Patents

Derivados de tetrahidroquinolina como moduladores de la hormona foliculo estimulante

Info

Publication number
PE20030273A1
PE20030273A1 PE2002000581A PE2002000581A PE20030273A1 PE 20030273 A1 PE20030273 A1 PE 20030273A1 PE 2002000581 A PE2002000581 A PE 2002000581A PE 2002000581 A PE2002000581 A PE 2002000581A PE 20030273 A1 PE20030273 A1 PE 20030273A1
Authority
PE
Peru
Prior art keywords
alkyl
phenyl
tetrahydro
acetyl
stimulating hormone
Prior art date
Application number
PE2002000581A
Other languages
English (en)
Inventor
Jurgen Schulz
Straten Nicole Corine Renee Van
Someren Rudolf Gijsbertus Van
Original Assignee
Akzo Nobel Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel Nv filed Critical Akzo Nobel Nv
Publication of PE20030273A1 publication Critical patent/PE20030273A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/04—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms
    • C07D215/08—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms with acylated ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)

Abstract

SE REFIERE A DERIVADOS DE TETRAHIDROQUINOLINA DE FORMULA I DONDE R1 ES FORMILO, ALQUILCARBONILO C1-C6, ALQUILSULFONILO C1-C6; R2 Y R3 SON H, ALQUILO C1-C4, R4 ES FENILO; R5 ES ALQUILO C1-C4, Y-X ES COO, SO2O, NHCOO, NHCSO, OCOO, ENLACE-O, CONH, ENTRE OTROS; R6 ES H, EXCEPTO CUANDO Y-X ES UN ENLACE, TRIFLUOROMETILO, ALQUILO C1-C6, 1-ADAMANTIL-ALQUILO C1-C4, ALQUINILO C2-C6, HETEROARILO C3-C9, CICLOALQUILO C3-C6, ENTRE OTROS; R7 ES H, ALQUILO C1-C4, ALCOXI C1-C4, HALOGENO, TRIFLUOROMETILO, ENTRE OTROS; R8 Y R9 SON H, ALQUILO C1-C4, ALQUENILO C2-C4, ALQUINILO C2-C4, ARILO C6-C10, HETEROARILO C3-C9, ENTRE OTROS. SON COMPUESTOS PREFERIDOS 1-ACETIL-6-(TER-BUTOXICARBONIL)AMINO-4-FENIL-1,2,3,4-TETRAHIDRO-2,2,4-TRIMETILQUINOLINA; 1-ACETIL-6-(4-CLOROBENZOIL)-AMINO-4-FENIL-1,2,3,4-TETRAHIDRO-2,2,4-TRIMETILQUINOLINA, 1-ACETIL-6-BENZOILAMINO-4-FENIL-1,2,3,4-TETRAHIDRO-2,2,4-TRIMETILQUINOLINA, ENTRE OTROS. LOS COMPUESTOS TIENEN ACTIVIDAD MODULADORA DE LA HORMONA FOLICULO ESTIMULANTE FSH Y PUEDE SER UTIL PARA CONTROLAR LA FERTILIDAD
PE2002000581A 2001-07-02 2002-06-27 Derivados de tetrahidroquinolina como moduladores de la hormona foliculo estimulante PE20030273A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01202531 2001-07-02

Publications (1)

Publication Number Publication Date
PE20030273A1 true PE20030273A1 (es) 2003-03-21

Family

ID=8180574

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2002000581A PE20030273A1 (es) 2001-07-02 2002-06-27 Derivados de tetrahidroquinolina como moduladores de la hormona foliculo estimulante

Country Status (32)

Country Link
US (2) US8058441B2 (es)
EP (1) EP1406628B1 (es)
JP (1) JP4523273B2 (es)
KR (1) KR100908468B1 (es)
CN (1) CN1261099C (es)
AR (1) AR034669A1 (es)
AT (1) ATE319451T1 (es)
AU (1) AU2002317848B2 (es)
BR (1) BR0210645A (es)
CA (1) CA2452606C (es)
CY (1) CY1106087T1 (es)
CZ (1) CZ20042A3 (es)
DE (1) DE60209734T2 (es)
DK (1) DK1406628T3 (es)
EC (1) ECSP034932A (es)
ES (1) ES2260458T3 (es)
HK (1) HK1061810A1 (es)
HR (1) HRP20031080A2 (es)
HU (1) HUP0400390A2 (es)
IL (1) IL159288A0 (es)
IS (1) IS2418B (es)
MX (1) MXPA03011908A (es)
NO (1) NO325516B1 (es)
NZ (1) NZ530198A (es)
PE (1) PE20030273A1 (es)
PL (1) PL367638A1 (es)
PT (1) PT1406628E (es)
RU (1) RU2347570C2 (es)
SA (1) SA02230260B1 (es)
SK (1) SK286759B6 (es)
WO (1) WO2003004028A1 (es)
ZA (1) ZA200309921B (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2452606C (en) * 2001-07-02 2011-09-13 Akzo Nobel N.V. Tetrahydroquinoline derivatives
DE60325025D1 (de) * 2002-02-15 2009-01-15 Glaxo Group Ltd Modulatoren des vanilloidrezeptors
FR2836620B1 (fr) * 2002-02-28 2004-04-16 Snecma Services Instrument de projection thermique
SE0200920D0 (sv) * 2002-03-25 2002-03-25 Astrazeneca Ab Novel compounds
TWI322012B (en) * 2002-12-20 2010-03-21 Organon Nv Tetrahydroquinoline derivatives
TWI306855B (en) * 2002-12-20 2009-03-01 Organon Nv Tetrahydroquinoline derivatives
SE0300480D0 (sv) * 2003-02-21 2003-02-21 Astrazeneca Ab Novel compounds
EP1644042A1 (en) * 2003-05-29 2006-04-12 AstraZeneca AB A pharmaceutical composition containing a p2x7 receptor antagonist and methotrexate
WO2004105797A1 (en) * 2003-05-29 2004-12-09 Astrazeneca Ab A pharmaceutical composition comprising a p2x7 antagonist and sulfasalazine
BRPI0410739A (pt) * 2003-05-29 2006-06-27 Astrazeneca Ab composição farmacêutica compreendendo um antagonista do receptor p2x7 e um fator de necrose tumoral (alfa)
GB0312609D0 (en) * 2003-06-02 2003-07-09 Astrazeneca Ab Novel compounds
KR100554155B1 (ko) * 2003-06-09 2006-02-22 학교법인 포항공과대학교 금속/반도체 나노막대 이종구조를 이용한 전극 구조물 및그 제조 방법
SE0302139D0 (sv) * 2003-07-28 2003-07-28 Astrazeneca Ab Novel compounds
SE0302192D0 (sv) * 2003-08-08 2003-08-08 Astrazeneca Ab Novel compounds
SE0302488D0 (sv) * 2003-09-18 2003-09-18 Astrazeneca Ab New combination
SA05260265A (ar) * 2004-08-30 2005-12-03 استرازينيكا ايه بي مركبات جديدة
SE0402925D0 (sv) * 2004-11-30 2004-11-30 Astrazeneca Ab Novel Compounds
US7691848B2 (en) 2005-03-02 2010-04-06 Wyeth Pyrrolobenzodiazepine arylcarboxamides and derivatives thereof as follicle-stimulating hormone receptor antagonists
MX2007013745A (es) 2005-05-04 2008-01-24 Organon Nv Derivados de dihidropiridina.
UA92009C2 (ru) * 2005-05-04 2010-09-27 Н.В. Органон Производные 4-фенил-5-оксо-1,4,5,6,7,8-гексагидрохинолина для лечения бесплодия
UA92007C2 (ru) 2005-05-04 2010-09-27 Н.В. Органон Производные 4-фенил-5-оксо-1,4,5,6,7,8-гексагидрохинолина для лечения бесплодности
UA92008C2 (en) * 2005-05-04 2010-09-27 Н.В. Органон 4-PHENYL-5-OXO-l,4,5,6,7,8-HEXAHYDROQUINOLINE DERIVATIVES AS MEDICAMENTS FOR THE TREATMENT OF INFERTILITY
CN101213197A (zh) 2005-05-12 2008-07-02 惠氏公司 作为促卵泡激素受体(fsh－r)拮抗剂的吡咯并苯并二氮杂䓬以及杂环甲酰胺衍生物
US7678787B2 (en) 2005-06-09 2010-03-16 Wyeth Pyrrolobenzodiazepine pyridine carboxamides and derivatives as follicle-stimulating hormone receptor antagonists
JP2009504597A (ja) * 2005-08-10 2009-02-05 バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト アシルトリプトファノール
US20070060573A1 (en) * 2005-08-10 2007-03-15 Lars Wortmann Acyltryptophanols
US20080221195A1 (en) * 2006-12-13 2008-09-11 Lars Wortmann 1,2-diarylacetylene derivatives of acyltryptophanols
EP1932831A1 (en) * 2006-12-13 2008-06-18 Bayer Schering Pharma Aktiengesellschaft 1,2-Diarylacetylene Derivatives of Acyltryptophanols
TWI410422B (zh) * 2007-01-15 2013-10-01 Mitsubishi Tanabe Pharma Corp 縮合四氫喹啉衍生物及其醫藥用途
TW200848021A (en) 2007-03-06 2008-12-16 Wyeth Corp Sulfonylated heterocycles useful for modulation of the progesterone receptor
MX2009010059A (es) * 2007-03-22 2009-10-12 Astrazeneca Ab Derivados de quinolina para el tratamiento de enfermedades inflamatorias.
TW200918058A (en) * 2007-08-31 2009-05-01 Organon Nv TSH receptor antagonizing tetrahydroquinoline compounds
US8106073B2 (en) 2007-11-30 2012-01-31 Astrazeneca Ab Quinoline derivatives 057
TW200944523A (en) 2008-02-08 2009-11-01 Organon Nv (Dihydro)pyrrolo[2,1-a]isoquinolines
US20100061976A1 (en) * 2008-07-24 2010-03-11 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Method for treating or preventing osteoporosis by reducing follicle stimulating hormone to cyclic physiological levels in a mammalian subject
US8071587B2 (en) 2009-05-27 2011-12-06 N. V. Organon (Dihydro)imidazoiso[5,1-A]quinolines
TWI461426B (zh) * 2009-05-27 2014-11-21 Merck Sharp & Dohme （二氫）咪唑並異〔５，１－ａ〕喹啉類
US8431564B2 (en) 2009-07-29 2013-04-30 Merck Sharp & Dohme B.V. Ring-annulated dihydropyrrolo[2,1-α]isoquinolines
TW201116531A (en) 2009-07-29 2011-05-16 Organon Nv Ring-annulated dihydropyrrolo[2,1-a]isoquinolines
TW201116515A (en) 2009-07-31 2011-05-16 Organon Nv Dihydrobenzoindazoles
US8921562B2 (en) * 2010-10-08 2014-12-30 N30 Pharmaceuticals, Inc. Substituted quinoline compounds as S-nitrosoglutathione reductase inhibitors
US8546427B2 (en) * 2010-10-20 2013-10-01 Hoffmann-La Roche Inc. Tetrahydroquinoline derivatives
EP3174932B1 (en) 2014-07-30 2021-06-09 Henkel IP & Holding GmbH Cure accelerators for anaerobic curable compositions
EP3703692A4 (en) * 2017-11-01 2021-04-28 Merck Sharp & Dohme Corp. NEW SUBSTITUTED TETRAHYDROQUINOLINE COMPOUNDS USED AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2686182A (en) 1950-12-07 1954-08-10 Basf Ag O-hydroxy-dihydro-quinoline carboxylic acids
ES2054784T3 (es) 1987-08-08 1994-08-16 Akzo Nv Un metodo para la fabricacion de un implante.
EP1043326A1 (en) 1994-12-22 2000-10-11 Ligand Pharmaceuticals Incorporated Steroid receptor modulator compounds and methods
IL141063A (en) * 1998-08-07 2005-06-19 Applied Research Systems Derivatives of pyrrolidine-2-carboxylic acid and piperidine-2-carboxylic acids and pharmaceutical compositions comprising said derivatives for treating infertility
JP2000143636A (ja) * 1998-09-02 2000-05-26 Sumitomo Pharmaceut Co Ltd アミノ誘導体
US6200963B1 (en) * 1999-03-31 2001-03-13 American Home Products Corporation Aryl sulfonic acids as FSH antagonists
CA2452606C (en) 2001-07-02 2011-09-13 Akzo Nobel N.V. Tetrahydroquinoline derivatives
TWI322012B (en) 2002-12-20 2010-03-21 Organon Nv Tetrahydroquinoline derivatives
TWI306855B (en) 2002-12-20 2009-03-01 Organon Nv Tetrahydroquinoline derivatives

Also Published As

Publication number Publication date
AU2002317848B2 (en) 2006-08-31
US20120202996A1 (en) 2012-08-09
DE60209734D1 (de) 2006-05-04
CA2452606A1 (en) 2003-01-16
RU2347570C2 (ru) 2009-02-27
DK1406628T3 (da) 2006-07-03
RU2004102693A (ru) 2005-06-27
EP1406628B1 (en) 2006-03-08
KR20040030714A (ko) 2004-04-09
ECSP034932A (es) 2004-02-26
CN1529601A (zh) 2004-09-15
JP4523273B2 (ja) 2010-08-11
DE60209734T2 (de) 2006-08-31
HRP20031080A2 (en) 2004-04-30
EP1406628A1 (en) 2004-04-14
CY1106087T1 (el) 2011-06-08
US8258293B2 (en) 2012-09-04
AR034669A1 (es) 2004-03-03
NO20035763L (no) 2003-12-29
PL367638A1 (en) 2005-03-07
BR0210645A (pt) 2004-10-05
SK286759B6 (sk) 2009-05-07
MXPA03011908A (es) 2004-06-03
SA02230260B1 (ar) 2007-03-25
CN1261099C (zh) 2006-06-28
WO2003004028A1 (en) 2003-01-16
NZ530198A (en) 2005-11-25
ES2260458T3 (es) 2006-11-01
CZ20042A3 (en) 2004-04-14
IL159288A0 (en) 2004-06-01
ATE319451T1 (de) 2006-03-15
US20040236109A1 (en) 2004-11-25
IS2418B (is) 2008-10-15
KR100908468B1 (ko) 2009-07-21
US8058441B2 (en) 2011-11-15
IS7071A (is) 2003-12-11
PT1406628E (pt) 2006-06-30
HUP0400390A2 (hu) 2004-09-28
NO325516B1 (no) 2008-06-02
SK16342003A3 (sk) 2004-07-07
CA2452606C (en) 2011-09-13
HK1061810A1 (en) 2004-10-08
JP2004535456A (ja) 2004-11-25
ZA200309921B (en) 2005-03-22

Similar Documents

Publication Publication Date Title
PE20030273A1 (es) Derivados de tetrahidroquinolina como moduladores de la hormona foliculo estimulante
HUP0301201A2 (hu) Kinazolinonok és kinazolinonokat tartalmazó készítmények
PE20021081A1 (es) Aril y biaril piperidinas con actividad moduladora mch
PE20010741A1 (es) Derivados de piperazina como antagonistas de taquicininas
PE20010070A1 (es) COMPUESTOS DE PIRIMIDINONA COMO INHIBIDORES DE LA ENZIMA Lp-PLA2
ES2150911T3 (es) Composiciones para frenar la caida de los cabellos y para inducir y estimular su crecimiento, a base de 2,4-diaminopirimidina-3-oxido.
RU98123001A (ru) Арилпиримидиновые производные
PE20030012A1 (es) Composicion y actividad antiviral de derivados de indoloxoacetico piperazina sustituidos
PE20010211A1 (es) Compuestos de tiazol y composiciones farmaceuticas para inhibir las quinasas de proteina
PE20030238A1 (es) Uso de los antagonistas del receptor nk-1 para el tratamiento de lesiones cerebrales, espinales y neuronales
CO5231161A1 (es) 4-aminopicolinatos y su uso como herbicidas
PE20050525A1 (es) Derivados de pirazol sustituido y compuestos relacionados como antagonistas del receptor de bradiquinina b1
WO2004058759A8 (en) Aryl / hetaryl substituted imidazoquinolines
CO5280059A1 (es) Derivados de 2-ox-1-pirrolidina, procewo para prepararlos y sus aplicaciones
ATE327224T1 (de) Chinazolinone benutzende verfahren und zusammenstellungen
AU2003301020A8 (en) Isoquinolinone derivatives and their use as therapeutic agents
CO5271661A1 (es) Pirimidonas de bifenilo con actividad contra aterosclerosis
PE20011066A1 (es) PIRIDO [2,3-d] PIRIMIDIN-2,7-DIAMINAS INHIBIDORES DE CINASAS
ATE277889T1 (de) Aminobenzophenone als inhibitoren von il-1beta und tnf-alpha
PE20010039A1 (es) Derivados de esteres del acido carbamico como agonistas y/o antagonistas del receptor metabotropico del glutamato
TR200401546T4 (tr) Piperazin türevleri, hazırlanmaları ve merkezi sinir sistemi (CNS) bozukluklarının tedavisinde kullanımları
ATE316962T1 (de) Pyrimidin-derivate als selective inhibitoren von cox-2
DE69820159D1 (de) Therapeutisch nützliche Chinoline und Quinazoline
PT984938E (pt) Cianoguanidinas como inibidores da proliferacao celular
PE20030726A1 (es) 4-feniltetrahidroisoquinolinas sustituidas, proceso para su preparacion y composiciones farmaceuticas que las contienen

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed